Evidence mapPaperPMID 33533892Full record

ReviewCardiovascular research2022

Emerging views of statin pleiotropy and cholesterol lowering.

Dongbo Yu, James K Liao

Open access · greenAbstract readReview
In one paragraph

Review in Cardiovascular research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 6 pooled it
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 6 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dongbo YuSection of Cardiology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0002-7764-2728
James K LiaoSection of Cardiology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.ORCID 0000-0001-9679-4252
University of Chicago · US

Funding

Mechanisms Underlying Vascular AgingR01HL136962 · NHLBI · UNIVERSITY OF CHICAGO · PI JAMES Kuang-Jan LIAO · 2021 to 2021
$405k
NHLBI NIH HHS R01 HL136962
6 · The paper itself

Abstract

Over the past four decades, no class of drugs has had more impact on cardiovascular health than the 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors or statins. Developed as potent lipid-lowering agents, statins were later shown to reduce morbidity and mortality of patients who are at risk for cardiovascular disease. However, retrospective analyses of some of these clinical trials have uncovered some aspects of their clinical benefits that may be additional to their lipid-lowering effects. Such 'pleiotropic' effects of statins garnered intense interest and debate over its contribution to cardiovascular risk reduction. This review will provide a brief background of statin pleiotropy, assess the available clinical evidence for and against their non-lipid-lowering benefits, and propose future research directions in this field.

Indexed as

AnimalsAnti-Inflammatory AgentsBiomarkersCardiovascular DiseasesCholesterolDrug Therapy, CombinationDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsTreatment OutcomeAnti-Inflammatory AgentsBiomarkersCholesterolHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsCholesterol • HMG-CoA reductase inhibitors • Atherosclerosis • Inflammation

Identifiers

PMID33533892
PMCPMC8803071
OpenAlexW3126891026

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.